(Q38185691)

30 August 2017

title

Vandetanib for the treatment of thyroid cancer: an update (English)

1 reference

30 August 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Panagiotis Anagnostis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gerasimos E Krassas

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

6 February 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

30 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

469-481

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24502390%20AND%20SRC:MED&resulttype=core&format=json

Medullary thyroid cancer: management guidelines of the American Thyroid Association

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Novel molecular targeted therapies for refractory thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

The role of epidermal growth factor receptor in cancer metastasis and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Sorafenib in metastatic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.885015